Supported by an unrestricted educational grant from Myovant Sciences.
November 15th, 2026Five Under 5: Top Oncology Videos for the Week of 11/8The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.Read more
November 12th, 2026FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate CancerPhase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.Read more
November 10th, 2026Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate CancerExperts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.Read more
November 8th, 2026JNJ-87189401 Plus Pasritamig Drives Deep PSA Responses With Favorable Safety in Pretreated mCRPCA dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.Read more
November 6th, 2026PSMA Radioligand Therapy Spans Metastatic Prostate Cancer as Next-Generation Theranostics EmergeDavid VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.Read more
November 6th, 2026Updated CAPItello-281 Data Support OS Advantage With Capivasertib in PTEN-Deficient mHSPCLonger follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.Read more